The concentration of the Magnificent Seven within the S&P 500 (SP500) continued to expand in 2024, with the group now accounting for a third of the benchmark in ...
- Dan Monahan will lead the commercialization strategy across Amylyx’ product portfolio, beginning with avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor ...